{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:47:50Z","timestamp":1788410870540,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04414-y","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:23:19Z","timestamp":1780388599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrated immunophenotypic and ProMisE molecular profiling as predictors of immune checkpoint inhibitor response in recurrent endometrial cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Komei","family":"Katayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kae","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Kubokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Iyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumi","family":"Utsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyosumi","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"4414_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"4414_CR2","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","volume":"387","author":"P Morice","year":"2016","unstructured":"Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E (2016) Endometrial cancer. Lancet 387:1094\u20131108. https:\/\/doi.org\/10.1016\/S0140-6736(15)00130-0","journal-title":"Lancet"},{"key":"4414_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40661-017-0056-7","volume":"4","author":"V Makker","year":"2017","unstructured":"Makker V, Green AK, Wenham RM, Mutch D, Davidson B, Miller DS (2017) New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecol Oncol Res Pract 4:19. https:\/\/doi.org\/10.1186\/s40661-017-0056-7","journal-title":"Gynecol Oncol Res Pract"},{"key":"4414_CR4","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1200\/JCO.19.02627","volume":"38","author":"V Makker","year":"2020","unstructured":"Makker V, Taylor MH, Aghajanian C et al (2020) Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 38:2981\u20132992. https:\/\/doi.org\/10.1200\/JCO.19.02627","journal-title":"J Clin Oncol"},{"key":"4414_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2019","unstructured":"Marabelle A, Le DT, Ascierto PA et al (2019) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38:1\u201310. https:\/\/doi.org\/10.1200\/JCO.19.02105","journal-title":"J Clin Oncol"},{"key":"4414_CR6","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/cncr.30496","volume":"123","author":"A Talhouk","year":"2017","unstructured":"Talhouk A, McConechy MK, Leung S et al (2017) Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 123:802\u2013813. https:\/\/doi.org\/10.1002\/cncr.30496","journal-title":"Cancer"},{"key":"4414_CR7","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","volume":"29","author":"S Kommoss","year":"2018","unstructured":"Kommoss S, McConechy MK, Kommoss F et al (2018) Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 29:1180\u20131188. https:\/\/doi.org\/10.1093\/annonc\/mdy058","journal-title":"Ann Oncol"},{"key":"4414_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409\u2013413. https:\/\/doi.org\/10.1126\/science.aan6733","journal-title":"Science"},{"key":"4414_CR9","doi-asserted-by":"publisher","first-page":"1035616","DOI":"10.3389\/fimmu.2022.1035616","volume":"13","author":"Y Dai","year":"2022","unstructured":"Dai Y, Zhao L, Hua D et al (2022) Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study. Front Immunol 13:1035616. https:\/\/doi.org\/10.3389\/fimmu.2022.1035616","journal-title":"Front Immunol"},{"key":"4414_CR10","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1200\/JCO.21.01874","volume":"40","author":"DM O\u2019Malley","year":"2022","unstructured":"O\u2019Malley DM, Bariani GM, Cassier PA et al (2022) Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol 40:752\u2013761. https:\/\/doi.org\/10.1200\/JCO.21.01874","journal-title":"J Clin Oncol"},{"key":"4414_CR11","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.3390\/cancers17152420","volume":"17","author":"C Pizzimenti","year":"2025","unstructured":"Pizzimenti C, Fiorentino V, Pepe L, Franchina M, Ruggeri C, Ercoli A, Ciappina G, Berretta M, Tuccari G, Ieni A (2025) Predictive biomarkers for immunotherapy in endometrial carcinoma. Cancers 17:2420. https:\/\/doi.org\/10.3390\/cancers17152420","journal-title":"Cancers"},{"key":"4414_CR12","doi-asserted-by":"publisher","first-page":"e009143","DOI":"10.1136\/jitc-2024-009143","volume":"12","author":"JF Grau Bejar","year":"2024","unstructured":"Grau Bejar JF, Yaniz Galende E, Zeng Q et al (2024) Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer. J Immunother Cancer 12:e009143. https:\/\/doi.org\/10.1136\/jitc-2024-009143","journal-title":"J Immunother Cancer"},{"key":"4414_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s00262-024-03919-8","volume":"74","author":"S Hattori","year":"2025","unstructured":"Hattori S, Yoshikawa N, Liu W et al (2025) Understanding the impact of spatial immunophenotypes on the survival of endometrial cancer patients through the ProMisE classification. Cancer Immunol Immunother 74:70. https:\/\/doi.org\/10.1007\/s00262-024-03919-8","journal-title":"Cancer Immunol Immunother"},{"key":"4414_CR14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00262-009-0781-9","volume":"59","author":"H Suzuki","year":"2010","unstructured":"Suzuki H, Chikazawa N, Tasaka T et al (2010) Intratumoral CD8+ T\/FOXP3+ cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol Immunother 59:653\u2013661. https:\/\/doi.org\/10.1007\/s00262-009-0781-9","journal-title":"Cancer Immunol Immunother"},{"key":"4414_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ygyno.2009.03.022","volume":"114","author":"RA de Jong","year":"2009","unstructured":"de Jong RA, Leffers N, Boezen HM, ten Hoor KA, van der Zee AGJ, Hollema H, Nijman HW (2009) Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol 114:105\u2013110. https:\/\/doi.org\/10.1016\/j.ygyno.2009.03.022","journal-title":"Gynecol Oncol"},{"key":"4414_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ygyno.2008.04.021","volume":"110","author":"A Giatromanolaki","year":"2008","unstructured":"Giatromanolaki A, Bates GJ, Koukourakis MI, Sivridis E, Gatter KC, Harris AL, Banham AH (2008) The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol Oncol 110:216\u2013221. https:\/\/doi.org\/10.1016\/j.ygyno.2008.04.021","journal-title":"Gynecol Oncol"},{"key":"4414_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Allavena P, Marchesi F, Garlanda C (2022) Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov 21:799\u2013820. https:\/\/doi.org\/10.1038\/s41573-022-00520-5","journal-title":"Nat Rev Drug Discov"},{"key":"4414_CR18","doi-asserted-by":"publisher","first-page":"583084","DOI":"10.3389\/fimmu.2020.583084","volume":"11","author":"Y Pan","year":"2020","unstructured":"Pan Y, Yu Y, Wang X, Zhang T (2020) Tumor-associated macrophages in tumor immunity. Front Immunol 11:583084. https:\/\/doi.org\/10.3389\/fimmu.2020.583084","journal-title":"Front Immunol"},{"key":"4414_CR19","doi-asserted-by":"publisher","first-page":"175883592513473","DOI":"10.1177\/17588359251347364","volume":"17","author":"O Le Saux","year":"2025","unstructured":"Le Saux O, Sabatier R, Treilleux I et al (2025) Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacy. Ther Adv Med Oncol 17:17588359251347364. https:\/\/doi.org\/10.1177\/17588359251347364","journal-title":"Ther Adv Med Oncol"},{"key":"4414_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ygyno.2016.08.325","volume":"143","author":"RM Brightwell","year":"2016","unstructured":"Brightwell RM, Grzankowski KS, Lele S, Eng K, Arshad M, Chen H, Odunsi K (2016) The CD47 don\u2019t eat me signal is highly expressed in human ovarian cancer. Gynecol Oncol 143:393\u2013397. https:\/\/doi.org\/10.1016\/j.ygyno.2016.08.325","journal-title":"Gynecol Oncol"},{"key":"4414_CR21","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1158\/1078-0432.CCR-14-2520","volume":"21","author":"MN McCracken","year":"2015","unstructured":"McCracken MN, Cha AC, Weissman IL (2015) Molecular pathways: activating T cells after cancer cell phagocytosis from blockade of CD47 don\u2019t eat me signals. Clin Cancer Res 21:3597\u20133601. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2520","journal-title":"Clin Cancer Res"},{"key":"4414_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","volume":"24","author":"MP Chao","year":"2012","unstructured":"Chao MP, Weissman IL, Majeti R (2012) The CD47-SIRP\u03b1 pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 24:225\u2013232. https:\/\/doi.org\/10.1016\/j.coi.2012.01.010","journal-title":"Curr Opin Immunol"},{"key":"4414_CR23","doi-asserted-by":"publisher","first-page":"pgaf143","DOI":"10.1093\/pnasnexus\/pgaf143","volume":"4","author":"K Yucebas","year":"2025","unstructured":"Yucebas K, Ko S, Zhou J et al (2025) Immunotherapy of endometrial cancer via CD47 blockade-mediated macrophage phagocytosis. PNAS Nexus 4:pgaf143. https:\/\/doi.org\/10.1093\/pnasnexus\/pgaf143","journal-title":"PNAS Nexus"},{"key":"4414_CR24","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","volume":"22","author":"E Picarda","year":"2016","unstructured":"Picarda E, Ochaegbulam KC, Zang X (2016) Molecular pathways: targeting B7\u2013H3 (CD276) for human cancer immunotherapy. Clin Cancer Res 22:3425\u20133431. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2428","journal-title":"Clin Cancer Res"},{"key":"4414_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.trecan.2018.03.010","volume":"4","author":"K Flem-Karlsen","year":"2018","unstructured":"Flem-Karlsen K, Fodstad O, Tan M, Nunes-Xavier CE (2018) B7\u2013H3 in cancer-beyond immune regulation. Trends Cancer 4:401\u2013404. https:\/\/doi.org\/10.1016\/j.trecan.2018.03.010","journal-title":"Trends Cancer"},{"key":"4414_CR26","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2147\/ITT.S534666","volume":"14","author":"B Larkin","year":"2025","unstructured":"Larkin B, Nishizaki D, Miyashita H et al (2025) B7\u2013H3\/CD276: novel immune checkpoint and jack of all trades. Immunotargets Ther 14:967\u2013977. https:\/\/doi.org\/10.2147\/ITT.S534666","journal-title":"Immunotargets Ther"},{"key":"4414_CR27","doi-asserted-by":"publisher","first-page":"1684549","DOI":"10.3389\/fimmu.2025.1684549","volume":"16","author":"L Zhao","year":"2025","unstructured":"Zhao L, Li X, Jing Y et al (2025) Biomarkers and immunotherapy in endometrial cancer: mechanisms and clinical applications. Front Immunol 16:1684549. https:\/\/doi.org\/10.3389\/fimmu.2025.1684549","journal-title":"Front Immunol"},{"key":"4414_CR28","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.1111\/cas.15460","volume":"113","author":"H Yamazaki","year":"2022","unstructured":"Yamazaki H, Asano H, Hatanaka KC, Matsuoka R, Konno Y, Matsuno Y, Hatanaka Y, Watari H (2022) The prognosis of endometrial cancers stratified with conventional risk factors and modified molecular classification. Cancer Sci 113:3134\u20133147. https:\/\/doi.org\/10.1111\/cas.15460","journal-title":"Cancer Sci"},{"key":"4414_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/path.5372","volume":"250","author":"A Le\u00f3n-Castillo","year":"2020","unstructured":"Le\u00f3n-Castillo A, Britton H, McConechy MK et al (2020) Interpretation of somatic POLE mutations in endometrial carcinoma. J Pathol 250:323\u2013335. https:\/\/doi.org\/10.1002\/path.5372","journal-title":"J Pathol"},{"key":"4414_CR30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3109\/00313025.2010.493871","volume":"42","author":"G Hall","year":"2010","unstructured":"Hall G, Clarkson A, Shi A, Langford E, Leung H, Eckstein RP, Gill AJ (2010) Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. Pathology 42:409\u2013413. https:\/\/doi.org\/10.3109\/00313025.2010.493871","journal-title":"Pathology"},{"key":"4414_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry S, Salgado R, Gevaert T et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 24:311\u2013335. https:\/\/doi.org\/10.1097\/PAP.0000000000000161","journal-title":"Adv Anat Pathol"},{"key":"4414_CR32","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.3390\/cancers14163911","volume":"14","author":"MN Mamat Yusof","year":"2022","unstructured":"Mamat Yusof MN, Chew KT, Kampan N, Abd Aziz NH, Md Zin RR, Tan GC, Shafiee MN (2022) PD-L1 expression in endometrial cancer and its association with clinicopathological features: a systematic review and meta-analysis. Cancers 14:3911. https:\/\/doi.org\/10.3390\/cancers14163911","journal-title":"Cancers"},{"key":"4414_CR33","doi-asserted-by":"publisher","first-page":"105704","DOI":"10.1016\/j.humpath.2024.105704","volume":"154","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Ju B, Cheng R, Ding T, Wu J (2024) PD-L1 expression and immune infiltration across molecular subtypes of endometrial cancer: an integrative-analysis of molecular classification and immune subtypes. Hum Pathol 154:105704. https:\/\/doi.org\/10.1016\/j.humpath.2024.105704","journal-title":"Hum Pathol"},{"key":"4414_CR34","doi-asserted-by":"publisher","first-page":"1633260","DOI":"10.3389\/fonc.2025.1633260","volume":"15","author":"D Fanale","year":"2025","unstructured":"Fanale D, Corsini LR, Piraino P et al (2025) POLE-mutated endometrial cancer: new perspectives on the horizon? Front Oncol 15:1633260. https:\/\/doi.org\/10.3389\/fonc.2025.1633260","journal-title":"Front Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04414-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04414-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04414-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T23:46:53Z","timestamp":1785973613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04414-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4414"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04414-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8733104\/v1","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Nagoya University (approval number: 2018-0400).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in all Figures.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"201"}}